Jennifer Kim
Stock Analyst at Cantor Fitzgerald
(1.72)
# 3,001
Out of 4,789 analysts
41
Total ratings
37.5%
Success rate
-1.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jennifer Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Reiterates: Overweight | n/a | $66.22 | - | 4 | Mar 18, 2025 | |
| INSM Insmed | Reiterates: Overweight | n/a | $76.29 | - | 8 | Feb 20, 2025 | |
| FBIO Fortress Biotech | Reiterates: Overweight | n/a | $1.56 | - | 4 | Jun 20, 2024 | |
| EYPT EyePoint Pharmaceuticals | Reiterates: Overweight | n/a | $5.42 | - | 6 | Jun 20, 2024 | |
| ALLK Allakos | Reiterates: Neutral | n/a | $0.23 | - | 4 | Jun 20, 2024 | |
| PGEN Precigen | Reiterates: Overweight | n/a | $1.49 | - | 3 | May 15, 2024 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $0.71 | +183.17% | 2 | Aug 31, 2023 | |
| CKPT Checkpoint Therapeutics | Maintains: Overweight | $19 → $14 | $4.04 | +246.53% | 4 | Aug 15, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $3.18 | +937.74% | 2 | Jul 27, 2023 | |
| PRQR ProQR Therapeutics | Maintains: Overweight | $5 → $4.5 | $1.33 | +238.35% | 2 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $100 | $1.20 | +8,233.33% | 2 | May 17, 2022 |
Belite Bio
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $66.22
Upside: -
Insmed
Feb 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $76.29
Upside: -
Fortress Biotech
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.56
Upside: -
EyePoint Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.42
Upside: -
Allakos
Jun 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.23
Upside: -
Precigen
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.49
Upside: -
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $0.71
Upside: +183.17%
Checkpoint Therapeutics
Aug 15, 2023
Maintains: Overweight
Price Target: $19 → $14
Current: $4.04
Upside: +246.53%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $3.18
Upside: +937.74%
ProQR Therapeutics
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $1.33
Upside: +238.35%
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $1.20
Upside: +8,233.33%